Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group

Trial Profile

Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2018 Primary endpoint (Progression free survival rate) has been met as per the results published in the Lancet Oncology
    • 09 Feb 2018 Results published in the Lancet Oncology
    • 24 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top